The Safety Profiles of Adalimumab, Infliximab, Etanercept, Secukinumab and Ustekinumab in Psoriasis – A 30-month Observational Cohort Prospective Study of Adverse Events in Biologic Therapy

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064173%3A_____%2F24%3A43929415" target="_blank" >RIV/00064173:_____/24:43929415 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11120/24:43929415 RIV/00216208:11130/24:10510272 RIV/00064165:_____/24:10510272

Result on the web

<a href="https://actadermatovenerologicacroatica.hr/wp-content/uploads/2025/11/2-Paluch.pdf" target="_blank" >https://actadermatovenerologicacroatica.hr/wp-content/uploads/2025/11/2-Paluch.pdf</a>

DOI - Digital Object Identifier

—

Result language

angličtina

Original language name

The Safety Profiles of Adalimumab, Infliximab, Etanercept, Secukinumab and Ustekinumab in Psoriasis – A 30-month Observational Cohort Prospective Study of Adverse Events in Biologic Therapy

Original language description

Background: Although biologic agents are very effective, long-term comparative studies demonstrating their safety relative to one another are still lacking. Methods: A total of 124 patients with psoriasis were followed up for 30 months; 74 received anti-TNF-alpha inhibitors (adalimumab, etanercept, infliximab), 33 were on ustekinumab, and 17 were treated with secukinumab. The rates of adverse events in these groups were recorded and statistically analyzed. Results: Infliximab-treated patients showed a high occurrence of asymptomatic, but increased liver enzymes, fatigue, and respiratory as well as dermatologic infections. Adalimumab-treated patients were more often affected by musculoskeletal disorders and infections of all types. Patients treated with secukinumab presented with higher rates of cardiovascular disorders as well as respiratory and dermatologic infections. The group receiving etanercept was more often diagnosed with musculoskeletal and reproductive disorders, specifically menstrual disorders. The rates of therapy discontinuation and serious adverse events did not reach statistically significant values. Conclusion: A higher incidence of adverse events was observed among adalimumab-, and infliximab-treated patients, with ustekinumab found to have the safest profile. Our results demonstrate that a personalized approach, including evaluation of a patient&apos;s risk profile, is necessary before commencing a biologic. Further research is warranted to confirm the findings of our study.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30216 - Dermatology and venereal diseases

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2024

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Acta Dermatovenerologica Croatica

ISSN

1330-027X

e-ISSN

1847-6538

Volume of the periodical

32

Issue of the periodical within the volume

1

Country of publishing house

HR - CROATIA

Number of pages

10

Pages from-to

7-16

UT code for WoS article

001673747900002

EID of the result in the Scopus database

2-s2.0-85197609078